STOK: Stoke Therapeutics, Inc. Market Value

The rare disease therapy market is currently experiencing a colossal shortage of effective solutions, making the price indicator on the GURU.Markets chart a critical analysis tool. Stoke Therapeutics is accelerating drug launches through partnerships with global pharma behemoths. Leveraging unique RNA correction methods, the company is positioned for exclusive leadership in its niche, which will enable premium pricing power. Current market capitalization stands at 1.80.

STOK stoketherapeutics.com: Market Capitalization in the range 07/04/2022 - 11/12/2026

Stoke Corp - analytical breakdowns and key metrics (STOK)

- stock price and consensus target price:

Stock Quotes Stoke Therapeutics, Inc.|STOK - Analyst Forecast Prices

- market capitalization information:

Market Value Stoke Corp|STOK - Total Enterprise Value

- book value of equity indicators:

Net Assets per Single Share Stoke Therapeutics|STOK - Book Capitalization|Market Capitalization to Book Value Ratio stoketherapeutics.com|STOK - Total Business Assets

- debt and liquidity data:

- business earnings and investment ratios data:

STOK - Company Net Income|Expected Profit Stoke Therapeutics|STOK - P/E Multiple|Forward P/E Multiple Stoke|STOK - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio Stoke Corp|STOK - Income before deduction of interest, taxes and amortization|Net earnings per share for the last 12 months Stoke Therapeutics|STOK - Earnings per share for the last four quarters|Quarterly EPS earnings growth stoketherapeutics.com|STOK - Earnings per share increase in current year|Earnings growth forecast for next year Stoke Therapeutics

Fundamental company analysis:STOK (Stoke Therapeutics, Inc.)

Market capitalization represents the aggregate value of all shares, calculated as the product of the current closing price and the total number of securities. By analyzing the capitalization dynamics of the issuer, an investor assesses the asset's liquidity and its resilience to volatility, which for RNA therapy pioneer Stoke Therapeutics (STOK) reflects market confidence in scientific breakthroughs for the treatment of genetic epilepsy.

Analysis of competing companies